Natco Soars 11% After Approval to Roll Out WeightLoss Drug Semaglutide in March

Natco Pharma has witnessed a significant surge of 11% in its stock price following the announcement of regulatory approval for its weight-loss drug, Semaglutide. This prescription medication is primarily indicated for adults struggling with insufficiently controlled type 2 diabetes mellitus and is designed to be used alongside a proper diet and exercise regimen. The approval marks a pivotal moment for Natco, as it expands its portfolio in the competitive pharmaceutical landscape, particularly in the diabetes management sector. Semaglutide has gained recognition globally for its efficacy in weight management, which is increasingly becoming a critical concern in India, where rising obesity rates contribute to a surge in diabetes cases. The market's positive reaction reflects investor confidence in Natco's potential to capture a significant share of this lucrative market segment, especially as health awareness continues to grow among the Indian populace. As the company prepares for the drug's rollout in March, stakeholders will be keenly observing its impact on Natco's financial performance and market positioning in the coming quarters.